Last 47 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Boston Scientific Corporation's quarterly P/E stands at 53.0x, down 9.9% year-over-year.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 22.85 | 52.97 | 48.81 | 50.67 | 55.87 | 58.79 | 66.44 | 88.19 | 51.25 | 42.35 | 38.55 | 75.46 | 60.28 |
| — | -9.9% | -26.5% | -42.6% | +9.0% | +38.8% | +72.4% | +16.9% | -15.0% | -68.0% | -51.9% | +38.6% | -63.3% | |
| P/S Ratio | 3.28 | 6.75 | 7.21 | 7.92 | 8.08 | 7.30 | 7.40 | 6.94 | 6.58 | 5.73 | 5.52 | 5.47 | 5.34 |
| — | -7.5% | -2.7% | +14.2% | +22.7% | +27.3% | +34.1% | +26.8% | +23.3% | +11.3% | +25.5% | +32.5% | +1.4% | |
| P/B Ratio | 2.71 | 5.83 | 6.18 | 7.08 | 6.71 | 6.05 | 5.95 | 5.55 | 5.03 | 4.37 | 4.07 | 4.26 | 3.99 |
| — | -3.7% | +3.9% | +27.7% | +33.4% | +38.4% | +46.1% | +30.2% | +26.0% | +15.1% | +28.8% | +37.2% | +4.9% | |
| P/FCF | 18.01 | 35.20 | 31.41 | 36.59 | 106.37 | 28.61 | 44.64 | 43.43 | — | 30.93 | 39.57 | 43.57 | 262.11 |
| — | +23.0% | -29.6% | -15.8% | — | -7.5% | +12.8% | -0.3% | — | +12.5% | -15.4% | -34.3% | — | |
| EV / EBITDA | 20.43 | 40.01 | 28.16 | 37.21 | 33.09 | 38.38 | 34.00 | 28.90 | 29.05 | 26.98 | 25.10 | 25.85 | 25.36 |
| — | +4.3% | -17.2% | +28.7% | +13.9% | +42.2% | +35.5% | +11.8% | +14.6% | +6.8% | +16.0% | +25.6% | +1.5% | |
| EV / EBIT | 19.20 | 40.01 | 38.20 | 41.64 | 45.29 | 49.74 | 44.41 | 61.04 | 40.50 | 41.09 | 31.94 | 44.16 | 39.70 |
| — | -19.6% | -14.0% | -31.8% | +11.8% | +21.1% | +39.1% | +38.2% | +2.0% | +1.3% | -38.7% | +15.1% | -2.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Boston Scientific Corporation's operating margin was 22.8% in Q4 2025, up 2.1 pp QoQ and up 9.9 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 19.7% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 27.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.0% | 74.5% | 69.9% | 67.7% | 63.3% | 58.6% | 62.9% | 62.7% | 61.8% | 62.1% | 61.4% | 63.2% | 61.3% |
| — | +27.2% | +11.2% | +7.8% | +2.3% | -5.6% | +2.4% | -0.8% | +0.9% | +2.9% | +1.0% | +3.2% | +0.6% | |
| Operating Margin | 19.8% | 22.8% | 20.7% | 16.2% | 19.2% | 12.9% | 16.0% | 18.1% | 16.7% | 15.0% | 15.8% | 15.3% | 15.2% |
| — | +76.7% | +29.5% | -10.7% | +15.1% | -13.8% | +1.2% | +18.4% | +9.9% | +8.2% | +9.0% | +4.1% | +0.6% | |
| Net Margin | 14.4% | 12.6% | 14.9% | 15.7% | 14.5% | 12.4% | 11.1% | 7.9% | 12.8% | 13.5% | 14.3% | 7.5% | 9.3% |
| — | +1.8% | +33.8% | +99.2% | +12.8% | -8.3% | -22.0% | +4.8% | +38.3% | +213.3% | +141.0% | -6.4% | +152.6% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.4% | 2.8% | 3.3% | 3.5% | 3.0% | 2.6% | 2.3% | 1.6% | 2.5% | 2.6% | 2.7% | 1.5% | 1.8% |
| — | +5.4% | +44.6% | +121.3% | +21.9% | +1.1% | -15.8% | +7.7% | +41.4% | +227.9% | +148.7% | -3.5% | +164.4% | |
| ROA | 6.9% | 1.5% | 1.8% | 1.9% | 1.7% | 1.5% | 1.2% | 0.9% | 1.4% | 1.5% | 1.5% | 0.8% | 1.0% |
| — | +5.9% | +43.6% | +121.0% | +23.2% | +0.3% | -16.3% | +8.2% | +43.2% | +235.2% | +154.2% | +0.8% | +179.5% | |
| ROIC | 8.8% | 2.6% | 2.3% | 1.8% | 2.0% | 1.4% | 1.7% | 1.9% | 1.7% | 1.5% | 1.5% | 1.5% | 1.5% |
| — | +84.6% | +32.6% | -6.8% | +19.8% | -6.0% | +13.8% | +28.4% | +15.9% | +16.5% | +15.9% | +11.2% | +7.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Boston Scientific Corporation's Debt/EBITDA ratio is 13.0x, up from 8.7x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 49.5% YoY to 1.62x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.51 | 0.51 | 0.51 | 0.53 | 0.52 | 0.51 | 0.54 | 0.53 | 0.55 | 0.49 | 0.49 | 0.51 | 0.52 |
| — | +0.2% | -5.1% | +0.1% | -4.4% | +4.2% | +10.5% | +3.8% | +5.5% | -8.0% | -4.0% | -5.4% | -10.6% | |
| Debt / EBITDA | 3.33 | 12.99 | 8.65 | 10.41 | 9.59 | 11.90 | 11.48 | 10.34 | 11.60 | 10.90 | 10.83 | 11.14 | 11.71 |
| — | +9.2% | -24.6% | +0.7% | -17.4% | +9.2% | +6.0% | -7.2% | -0.9% | -12.8% | -9.8% | -9.1% | -11.6% | |
| Current Ratio | 1.62 | 1.62 | 1.51 | 1.37 | 1.45 | 1.08 | 1.48 | 1.61 | 1.66 | 1.32 | 1.42 | 1.29 | 1.40 |
| — | +49.5% | +1.7% | -14.9% | -12.9% | -18.1% | +4.4% | +25.0% | +19.2% | -12.8% | -2.0% | -1.4% | +17.9% | |
| Quick Ratio | 1.08 | 1.08 | 0.96 | 0.82 | 0.88 | 0.64 | 1.02 | 1.14 | 1.14 | 0.82 | 0.90 | 0.80 | 0.89 |
| — | +67.5% | -5.6% | -28.3% | -22.8% | -21.4% | +13.5% | +43.6% | +27.8% | -20.2% | -5.3% | -7.1% | +14.9% | |
| Interest Coverage | 10.70 | 10.62 | 11.79 | 11.47 | 10.25 | 5.20 | 9.05 | 6.19 | 9.44 | 8.54 | 10.07 | 7.00 | 7.63 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Deep dive into BSX consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BSX stock.
Boston Scientific Corporation's current P/E is 22.9x. The average P/E over the last 4 quarters is 52.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Boston Scientific Corporation's current operating margin is 19.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Boston Scientific Corporation's business trajectory between earnings reports.